• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 3, 2014

View Archived Issues

Omeros goes commercial as miosis drug Omidria prepares for market

Omeros Corp. began its transformation from a drug development company to a commercial venture Monday after the FDA green-lighted Omidria (phenylephrine and ketorolac injection) 1 percent/0.3 percent. The drug, formerly OMS302, was approved to maintain pupil size during cataract surgery or intraocular lens replacement (ILR) by preventing intraoperative pupil constriction, or miosis, and to reduce postoperative pain. Read More

Newlink's phase III patient picks, antibody levels IMPRESS

CHICAGO – With immuno-oncology all the rage, especially against melanoma, at the 50th annual meeting of American Society of Clinical Oncology, the pairing of potential new compounds with ipilimumab (Yervoy, Bristol-Myers Squibb Co.) proved a popular ploy. Read More

GIST data provide another potential Iclusig indication

Ariad Pharmaceuticals Inc. provided positive clinical data for Iclusig (ponatinib). The drug had a rocky start after receiving a December 2012 approval for use in patients with chronic, accelerated and blast phases of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) whose disease is resistant or intolerant to tyrosine kinase inhibitors (TKIs). Read More

Adherex reports positive data on hearing loss drug

Positive new phase III data showing Adherex Technologies Inc.'s sodium thiosulfate (STS) reduced hearing loss in children with cancer on cisplatin chemotherapy moved the company a step closer to filing a new drug application for the orphan drug next year. If approved it would become the first such therapy available in the U.S. Read More

Live longer and prosper, with melanoma

CHICAGO – Melanoma was the first cancer type in which immunotherapy went from promise to breakthrough, and the American Society of Clinical Oncology (ASCO) went back to those roots in its Monday press briefing, highlighting studies that explored the use of immunotherapy's founding father, Yervoy (ipilimumab, Bristol-Myers Squibb) in new ways, as well as other promising immunotherapies. Read More

FDA expands draft guidance on using the Animal Rule

Instead of finalizing its draft guidance on human drug development under the Animal Rule, the FDA is revising the 6-year-old proposed recommendations. Read More

Hyperglycemia eclipses promising PFS data for Clovis' CO-1686

Elevated glucose levels emerging in roughly one-fourth of lung cancer patients receiving Clovis Oncology Inc.'s next-generation EGFR inhibitor CO-1686 may have overshadowed the promising interim progression-free survival (PFS) rate presented at the American Society of Clinical Oncology meeting over the weekend, at least on Wall Street, but analysts say the targeted covalent inhibitor remains a contender against Astrazeneca plc's AZD9291. Read More

Forget those guidelines: With hard-to-beat NSCLC, 'Revel' in small victories

CHICAGO – Efficacy plus an acceptable safety profile add up to the prime outcome from a trial, but there's much value in lesser attempts, said Gregory Masters of the Helen F. Graham Cancer Center in Newark, Del., as he found himself defending the choice of a spotlighted study at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) over the weekend. Read More

Other news to note

Orion Corp., of Espoo, Finland, and Bayer AG, of Berlin, entered a global agreement for the development and commercialization of ODM-201, an oral androgen receptor inhibitor in development for treating patients with prostate cancer. Read More

Stock movers

Read More

Financings

Relypsa Inc., of Redwood City, Calif., said it secured a loan facility of up to $35 million with Oxford Finance LLC and Silicon Valley Bank (SVB). Read More

News from ASCO 2014

Incyte Corp., of Wilmington, Del. announced that preliminary results from an ongoing phase I/II study of INCB24360, its oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, combined with ipilimumab in patients with unresectable or metastatic melanoma, showed the combination was generally well tolerated and produced evidence of clinical response. Read More

In the clinic

Alkermes plc, of Dublin, reported the start of a second phase II study of its broad-spectrum oral antipsychotic ALKS 3831 in development for schizophrenia. It will assess the compound's efficacy, safety and tolerability in treating schizophrenia in patients with co-occurring alcohol use disorder, compared to olanzapine, an approved antipsychotic medicine. Read More

Pharma: In the clinic

Forest Laboratories Inc., of New York, reported that a pivotal phase III trial testing a combination of nebivolol and Basel, Switzerland-based Novartis AG's Diovan (valsartan) met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at eight weeks in patients with hypertension. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe